Drug Trial Radar · NCT04498117
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
615
Actual
Start
Aug 25, 2020
Primary completion
Dec 26, 2026
Study completion Aug 26, 2028
Sponsor
- Lead sponsor
- CanariaBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gynecologic Oncology Group; IQVIA Pty Ltd
- First posted
- Aug 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Conditions
- Carcinoma, Ovarian Epithelial
- Ovarian Neoplasms
- Ovarian Cancer
- Ovarian Serous Adenocarcinoma
- Fallopian Tube Neoplasms
- Fallopian Tube Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Peritoneal Cancer
- Peritoneal Carcinoma
- Peritoneal Neoplasms
Interventions
OregovomabBiological
2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
PaclitaxelDrug
175 mg/m\^2, every 3 weeks
CarboplatinDrug
AUC 6 IV Day 1 x 6 cycles (every 21 days)
PlaceboBiological
2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
CarboplatinDrug
AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator Assessed Progression Free SurvivalTime frame: Date of randomization until date of first documented disease progression or date of death from any cause, whichever comes first, at up to approximately 6 years.
Locations
148 sites in 14 countries. Site status is shown where the registry gives one.
Honor Health
Phoenix, Arizona
The University of Arizona Cancer Center
Tucson, Arizona
John Muir Health Clinical Research Center
Concord, California
Kaiser Permanente Southern California
Irvine, California
Moores UC San Diego Cancer Center
La Jolla, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Epic Care
Pleasant Hill, California
Kaiser Permanente Riverside Medical Center
Riverside, California
University of California, Davis Comprehensive Cancer Center
Sacramento, California
Contra Costa Oncology
Walnut Creek, California
John Muir Health Gynecologic Cancer Services
Walnut Creek, California
University of Colorado Health
Aurora, Colorado
University of Connecticut Health Center
Farmington, Connecticut
Smilow Cancer Hospital
New Haven, Connecticut
Yale University School of Medicine
New Haven, Connecticut
AdventHealth Orlando
Orlando, Florida
Women's Cancer Florida/Women's Cancer Associates
St. Petersburg, Florida
Lewis Cancer & Research Pavilion at St. Joseph's Candler
Savannah, Georgia
The Queens Medical Center
Honolulu, Hawaii
Kapiolani Medical Center for Women and Children/University of Hawaii
Honolulu, Hawaii
Parkview Research Center
Fort Wayne, Indiana
Women's Cancer Care/Mary Bird Perkins Cancer Center
Covington, Louisiana
Tufts Medical Center
Boston, Massachusetts
Lahey Hospital and Medical Center
Burlington, Massachusetts
MetroWest Medical Center
Farmington, Massachusetts
Lowell General Hospital
Lowell, Massachusetts
Tufts Medical Center Cancer Center in Stoneham
Stoneham, Massachusetts
UMass Memorial Medical Center
Worcester, Massachusetts
St. Joseph Mercy Hospital
Ann Arbor, Michigan
Sparrow Hospital
Lansing, Michigan
Minnesota Oncology Hematology - Mercy Hospital
Coon Rapids, Minnesota
Minnesota Oncology Hematology
Edina, Minnesota
University of Minnesota Health - Maple Grove Clinic
Maple Grove, Minnesota
Minnesota Oncology Hematology
Minneapolis, Minnesota
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota
Park Nicollet Frauenshuh Cancer Center
Saint Louis Park, Minnesota
Minnesota Oncology Hematology
Saint Paul, Minnesota
Nebraska Methodist Hospital
Omaha, Nebraska
Portsmouth Regional Hospital
Portsmouth, New Hampshire
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.